783-13-1

Basic information

• Product Name: 3-[4-(Trifluoromethoxy)phenyl]acrylic acid
• Synonyms: TIMTEC-BB SBB002369;RARECHEM BK HW 0215;3-[4-(TRIFLUOROMETHOXY)PHENYL]ACRYLIC ACID;4-(TRIFLUOROMETHOXY)CINNAMIC ACID;4-(Trifluoromethoxy)Cinamic Acid;4-(Trifluoromethoxy)cinnamicacid96%;3-[4-(Trifluoromethoxy)phenyl]acrylic acid, 3-[4-(Trifluoromethoxy)phenyl]prop-2-enoic acid;3-(4-Trifluoromethoxyphenyl)-2-propenoic acid
• CAS NO: 783-13-1
• Molecular Formula: C₁₀H₇F₃O₃
• Molecular Weight: 232.16
• Product Categories: Aromatic Cinnamic Acids, Esters and Derivatives
• Mol File: 783-13-1.mol
• Article Data: 6

Chemical Properties

• Melting Point: 178 °C
• Boiling Point: 296.6 °C at 760 mmHg
• Flash Point: 133.2 °C
• Appearance: /
• Density: 1.403 g/cm³
• Vapor Pressure: 0.000641mmHg at 25°C
• Storage Temp.: Sealed in dry,Room Temperature
• PKA: 4.29±0.10(Predicted)
• CAS DataBase Reference: 3-[4-(Trifluoromethoxy)phenyl]acrylic acid(CAS DataBase Reference)
• NIST Chemistry Reference: 3-[4-(Trifluoromethoxy)phenyl]acrylic acid(783-13-1)
• EPA Substance Registry System: 3-[4-(Trifluoromethoxy)phenyl]acrylic acid(783-13-1)

Safety Data

• Hazard Codes: Xi
• Statements: 36/37/38
• Safety Statements: 26-36/37/39-22
• HazardClass: IRRITANT
• Hazardous Substances Data: 783-13-1(Hazardous Substances Data)

Usage

Uses

Used in Organic Synthesis:
3-[4-(Trifluoromethoxy)phenyl]acrylic acid is used as a key intermediate in organic synthesis for the preparation of various complex organic molecules. Its unique structure and reactivity facilitate the formation of new chemical bonds and the synthesis of target compounds.
Used in Pharmaceutical Research:
In the pharmaceutical industry, 3-[4-(Trifluoromethoxy)phenyl]acrylic acid is utilized as a starting material or building block for the development of new drugs. Its unique structure and reactivity can be leveraged to design and synthesize bioactive molecules with potential therapeutic applications.
Used in Materials Science:
3-[4-(Trifluoromethoxy)phenyl]acrylic acid is employed in the development of new materials with specific properties. Its unique structure and reactivity can be utilized to create materials with tailored characteristics, such as improved stability, enhanced performance, or novel functionalities.
Used in the Synthesis of Complex Organic Molecules:
3-[4-(Trifluoromethoxy)phenyl]acrylic acid serves as a valuable building block for the synthesis of complex organic molecules. Its trifluoromethoxy group can be used to introduce new functional groups or modify existing ones, enabling the creation of diverse organic compounds with a wide range of applications.

InChI:InChI=1/C10H7F3O3/c11-10(12,13)16-8-4-1-7(2-5-8)3-6-9(14)15/h1-6H,(H,14,15)/p-1/b6-3+

Upstream product

• 659-28-9 p-trifluoromethoxybenzaldehyde 
• 141-82-2 malonic acid 

Downstream Products

• 259269-56-2 3-(4-trifluoromethoxy-phenyl)-acrylamide 
• 1425647-14-8 (E)-1-(trifluoromethoxy)-4-(3,3,3-trifluoroprop-1-en-1-yl)benzene 
• 1352428-62-6 C₃₁H₃₅F₃N₄O₃ 
• 306936-02-7 4-trifluoromethoxycinnamoyl chloride 

Relevant articles and documents

Chiral Cyclopentadienyl Iridium(III) Complexes Promote Enantioselective Cycloisomerizations Giving Fused Cyclopropanes

The cyclopentadienyl (Cp) group is a very important ligand for many transition-metal complexes which have been applied in catalysis. The availability of chiral cyclopentadienyl ligands (Cpx) lags behind other ligand classes, thus hampering the investigation of enantioselective processes. We report a library of chiral CpxIrIII complexes equipped with an atropchiral Cp scaffold. A robust complexation procedure reliably provides CpxIrIII complexes with tunable counterions. In a proof-of-concept application, the iodide-bearing members are shown to be highly selective for enyne cycloisomerization reactions. The dehydropiperidine-fused cyclopropane products are formed in good yields and enantioselectivities.

5,6,7,8-TETRAHYDRO-IMIDAZO[1,5-A]PYRAZINE DERIVATIVES

The invention relates to 5,6,7,8-tetrahydro-imidazo[1,5-a]pyrazine derivatives of formula (I),wherein X represents CH2 or O; R1 represents a phenyl group, which group is independently mono-, di-, or tri-substituted wherein the substituents are independently selected from the group consisting of (C1-4)alkyl, (C1-4)alkoxy, halogen, cyano, trifluoromethoxy and trifluoromethyl; R2 represents (C1-4)alkyl, (C1-4)alkoxy, (C2-4)alkenyl, halogen, cyano, hydroxymethyl, trifluoromethyl, C(O)NR5R6 or cyclopropyl; R3 represents (C1-4)alkyl, (C1-4)alkoxy-methyl or halogen; R4 represents (C1-4)alkyl; R5 represents hydrogen or (C1-4)alkyl; and R6 represents hydrogen or (C1-4)alkyl. The invention also relates to pharmaceutically acceptable salts of such compounds; and to the use of such compounds as medicaments; especially as orexin receptor antagonists.

Benzimidazole Modulators of VR1

The invention is directed to compounds of Formula (I): to pharmaceutical compositions containing such compounds and to methods of treatment using them.

Novel ether derivatives

The present invention provides the compounds of formula (I) their pharmaceutically acceptable salts or esters, enantiomeric forms, diastereoisomers and racemates, the preparation of the above-mentioned compounds, compositions containing them and their man

NOVEL THIOETHER DERIVATIVES

Objects of the present invention are the compounds of formula (I) their pharmaceutically acceptable salts, enantiomeric forms, diastereoisomers and racemates, the preparation of the above compounds, pharmaceutical compositions containing them and their ma

NOVEL OXAZOLE DERIVATIVES, THEIR MANUFACTURE AND USE AS PHARMACEUTICAL AGENTS

Object of the present invention are compounds of the general formla (1), their pharmaceutically acceptable salts, enantiomeric forms, diastereoisomers and racemates, the preparation of the above-mentioned compounds, medicaments containing them and thei